Recombinant human interleukin-3 in patients with hematopoietic failure.
Nine patients with bone marrow failure and prolonged severe cytopenias were treated with recombinant human interleukin-3 (rhIL-3) at doses ranging from 30 micrograms/m2 to 500 micrograms/m2. rhIL-3 was administered in a subcutaneous bolus injection daily for 15 days. Platelet counts increased by a mean of 6-fold (range: 1.3- to 14.3-fold) in five out of eight evaluable patients. Reticulocyte counts increased 2.9-fold in three patients, and neutrophil counts increased by a mean of 3.1-fold in all eight patients. Platelet transfusions could be discontinued after treatment with rhIL-3 in two out of three evaluable transfusion-dependent patients. Only mild side effects, mainly fever and headache, were observed. These results indicate that rhIL-3 functions as a multilineage hematopoietic growth factor in vivo in patients with secondary bone marrow failure.
Ganser
A
A
Abteilung für Hämatologie, Johann Wolfgang Goethe-Universität, Frankfurt, FRG.
Lindemann
A
A
Seipelt
G
G
Ottmann
O G
OG
Eder
M
M
Herrmann
F
F
Frisch
J
J
Schulz
G
G
Mertelsmann
R
R
Hoelzer
D
D
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects; D001772:Blood Cell Count; D001853:Bone Marrow / Q000473:pathology; D004341:Drug Evaluation; D005260:Female; D006402:Hematologic Diseases / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007377:Interleukin-3 / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000628:therapy; D010976:Platelet Count; D011832:Radiation Injuries / Q000150:complications; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use
D000970:Antineoplastic Agents; D007377:Interleukin-3; D011994:Recombinant Proteins